(PLRX) Pliant Therapeutics - Ratings and Ratios
Fibrosis, Liver Disease, Muscular Dystrophy, Solid Tumors
PLRX EPS (Earnings per Share)
PLRX Revenue
Description: PLRX Pliant Therapeutics
Pliant Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative treatments for fibrotic diseases and related conditions. The companys pipeline is centered around its lead candidate, bexotegrast, a dual selective inhibitor targeting specific integrins, which has shown promise in treating primary sclerosing cholangitis and is currently in phase 2a trials. Additionally, Pliant Therapeutics is advancing other potential therapies, including PLN-1474 for liver fibrosis associated with nonalcoholic steatohepatitis, PLN-101095 for solid tumors, and PLN-101325 for muscular dystrophies, such as Duchenne muscular dystrophy.
The companys therapeutic approach is grounded in its understanding of the role of integrins in fibrosis and related diseases. By targeting specific integrins, Pliant Therapeutics aims to modulate the fibrotic process, potentially offering new treatment options for patients with limited or no effective therapies available. The progress of its lead candidate and other pipeline assets will be crucial in determining the companys future prospects.
Analyzing the
Considering the
Forecasting the stocks performance using both
Additional Sources for PLRX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
PLRX Stock Overview
Market Cap in USD | 77m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Biotechnology |
IPO / Inception | 2020-06-03 |
PLRX Stock Ratings
Growth Rating | -83.8 |
Fundamental | -58.6 |
Dividend Rating | 0.0 |
Rel. Strength | -86.4 |
Analysts | 3.23 of 5 |
Fair Price Momentum | 0.87 USD |
Fair Price DCF | - |
PLRX Dividends
Currently no dividends paidPLRX Growth Ratios
Growth Correlation 3m | -46.4% |
Growth Correlation 12m | -78.3% |
Growth Correlation 5y | -65.4% |
CAGR 5y | -42.72% |
CAGR/Max DD 5y | -0.44 |
Sharpe Ratio 12m | 0.44 |
Alpha | -101.69 |
Beta | 1.165 |
Volatility | 116.83% |
Current Volume | 845.6k |
Average Volume 20d | 1018.2k |
Stop Loss | 1.3 (-7.1%) |
As of July 12, 2025, the stock is trading at USD 1.40 with a total of 845,589 shares traded.
Over the past week, the price has changed by +11.11%, over one month by -9.09%, over three months by +11.55% and over the past year by -87.38%.
No, based on ValueRay´s Fundamental Analyses, Pliant Therapeutics (NASDAQ:PLRX) is currently (July 2025) a stock to sell. It has a ValueRay Fundamental Rating of -58.56 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of PLRX is around 0.87 USD . This means that PLRX is currently overvalued and has a potential downside of -37.86%.
Pliant Therapeutics has received a consensus analysts rating of 3.23. Therefor, it is recommend to hold PLRX.
- Strong Buy: 1
- Buy: 1
- Hold: 11
- Sell: 0
- Strong Sell: 0
According to our own proprietary Forecast Model, PLRX Pliant Therapeutics will be worth about 1 in July 2026. The stock is currently trading at 1.40. This means that the stock has a potential downside of -29.29%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | 4.8 | 242.1% |
Analysts Target Price | 10.1 | 618.6% |
ValueRay Target Price | 1 | -29.3% |